Chondroitin sulphate: a focus on osteoarthritis

被引:157
作者
Bishnoi, Mamta [1 ]
Jain, Ankit [1 ]
Hurkat, Pooja [1 ]
Jain, Sanjay K. [1 ]
机构
[1] Dr Hari Singh Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar 470003, MP, India
关键词
Chondroitin sulfate; Osteoarthritis; Glucosamine; Glycosaminoglycanes; Anti-inflammatory; Targeting; Drug delivery; SYMPTOMATIC KNEE OSTEOARTHRITIS; DOUBLE-BLIND; HYALURONIC-ACID; GLUCOSAMINE HYDROCHLORIDE; ARTICULAR-CARTILAGE; INDUCED ARTHRITIS; SYNOVIAL-FLUID; TENASCIN-C; RECEPTOR; URIC-ACID;
D O I
10.1007/s10719-016-9665-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Chondroitin sulfate (CS) being a natural glycosaminoglycan is found in the cartilage and extracellular matrix. It shows clinical benefits in symptomatic osteoarthritis (OA) of the finger, knee, hip joints, low back, facial joints and other diseases due to its anti-inflammatory activity. It also helps in OA by providing resistance to compression, maintaining the structural integrity, homeostasis, slows breakdown and reduces pain in sore muscles. It is most often used in combination with glucosamine to treat OA. CS is a key role player in the regulation of cell development, cell adhesion, proliferation, and differentiation. Its commercial applications have been continuously explored in the engineering of biological tissues and its combination with other biopolymers to formulate scaffolds which promote and accelerate the regeneration of damaged structure. It is approved in the USA as a dietary supplement for OA, while it is used as a symptomatic slowacting drug (SYSADOA) in Europe and some other countries. Any significant side effects or overdoses of CS have not been reported in clinical trials suggesting its long-term safety. This review highlights the potential of CS, either alone or in combination with other drugs, to attract the scientists engaged in OA treatment and management across the world.
引用
收藏
页码:693 / 705
页数:13
相关论文
共 136 条
[41]
Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? [J].
Hochberg, M. ;
Chevalier, X. ;
Henrotin, Y. ;
Hunter, D. J. ;
Uebelhart, D. .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (03) :259-267
[42]
Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration [J].
Hochberg, M. C. .
OSTEOARTHRITIS AND CARTILAGE, 2010, 18 :S28-S31
[43]
Association of proteoglycan degradation with catabolic cytokine and stromelysin release from cartilage cultured with fibronectin fragments [J].
Homandberg, GA ;
Hui, F .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 334 (02) :325-331
[44]
Folate-mediated chondroitin sulfate-Pluronic® 127 nanogels as a drug carrier [J].
Huang, Shih-Jer ;
Sun, Shuo-Li ;
Feng, Tzu-Hua ;
Sung, Kuo-Hsun ;
Lui, Wen-Ling ;
Wang, Li-Fang .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 38 (01) :64-73
[45]
Anti-arthritic Action Mechanisms of Natural Chondroitin Sulfate in Human Articular Chondrocytes and Synovial Fibroblasts [J].
Imada, Keisuke ;
Oka, Hideki ;
Kawasaki, Daisuke ;
Miura, Naoyoshi ;
Sato, Takashi ;
Ito, Akira .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (03) :410-414
[46]
Alterations in the chondroitin sulfate chain in human osteoarthritic cartilage of the knee [J].
Ishimaru, D. ;
Sugiura, N. ;
Akiyama, H. ;
Watanabe, H. ;
Matsumoto, K. .
OSTEOARTHRITIS AND CARTILAGE, 2014, 22 (02) :250-258
[47]
The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination [J].
Jackson, C. G. ;
Plaas, A. H. ;
Sandy, J. D. ;
Hua, C. ;
Kim-Rolands, S. ;
Barnhill, J. G. ;
Harris, C. L. ;
Clegg, D. O. .
OSTEOARTHRITIS AND CARTILAGE, 2010, 18 (03) :297-302
[48]
Jain A, 2015, HANDBOOK OF POLYMERS FOR PHARMACEUTICAL TECHNOLOGIES: VOL 3, BIODEGRADABLE POLYMERS, P105
[49]
Jain A, 2013, CRIT REV THER DRUG, V30, P91
[50]
Ji D, 2007, J AOAC INT, V90, P659